Latest publications

Practical Management of the JAK1 Inhibitor Abrocitinib for Atopic Dermatitis in Clinical Practice: Special Safety Considerations. Gooderham MJ, De Bruin-Weller M, Weidinger S, Cork MJ, Eichenfield LF, Simpson EL et al. Dermatol Ther (Heidelb) 2024 Jul 02

Performance of high dose omalizumab in chronic urticaria is predicted by initial improvement to standard dose. Simons JVL, Soegiharto R, Knulst AC, Van den Reek JMPA, Rockmann H et al. J Allergy Clin Immunol Pract 2024 Jun 19

The effect of subcutaneous and sublingual birch pollen immunotherapy on birch pollen-related food allergy: a systematic review. Kallen EJJ, Welsing PMJ, Löwik JM, Van Ree R, Knulst AC, Le TM et al. Front Allergy 2024; 5:1360073

Effect of dupilumab on asthma and aeroallergen sensitization in pediatric atopic dermatitis patients: Results of the BioDay registry. Rijst LPV, Groot KMW, Zuithoff NPA, De Bruin-Weller MS, De Graaf M et al. Pediatr Allergy Immunol 2024 Jun; 35(6):e14178

Targeted Combined Endpoint Improvement in Patient and Disease Domains in Atopic Dermatitis: A Treat-to-Target Analysis of Adults with Moderate-to-Severe Atopic Dermatitis Treated with Upadacitinib. Kwatra SG, De Bruin-Weller M, Silverberg JI, Lio P, Deleuran M, Aydin H et al. Acta Derm Venereol 2024 May 06; 104:adv18452

Lebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis. Simpson EL, De Bruin-Weller M, Hong HC, Staumont-Sallé D, Blauvelt A, Eyerich K et al. Dermatol Ther (Heidelb) 2024 May; 14(5):1145-1160

Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2). Simpson EL, Prajapati VH, Leshem YA, Chovatiya R, De Bruin-Weller MS, Ständer S et al. Dermatol Ther (Heidelb) 2024 May; 14(5):1127-1144

The pleiotropic role of IL-13 in AD pathogenesis. Dekkers C, De Bruin-Weller M et al. Br J Dermatol 2024 Apr 25

Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: Up to 5-year results from the daily practice BioDay registry. Zhang J, Boesjes CM, Loman L, Kamphuis E, Romeijn MLE, Spekhorst LS et al. J Am Acad Dermatol 2024 Apr 21

House dust mite sublingual allergen immunotherapy tablet is safe and well-tolerated in Dutch clinical practice. Tempels-Pavlica Ž, Aarts MCJ, Welsing PMJ, Van der Meer AN, Van der Zwan LP, Uss E et al. Front Allergy 2024; 5:1355324

Ocular surface disease in moderate-to-severe atopic dermatitis patients and the effect of biological therapy. Achten R, Thijs J, Van der Wal M, Van Luijk C, Bakker D, Knol E et al. Clin Exp Allergy 2024 Apr; 54(4):241-252

Real-world Experience of Abrocitinib Treatment in Patients with Atopic Dermatitis and Hand Eczema: Up to 28-week Results from the BioDay Registry. Kamphuis E, Boesjes CM, Loman L, Kamsteeg M, Haeck I, Van Lynden-van Nes AMT et al. Acta Derm Venereol 2024 Feb 07; 104:adv19454

Influence of pathogenic filaggrin variants on dupilumab treatment in atopic dermatitis. Clabbers J, Boesjes C, Spekhorst L, Van Gisbergen MW, Maas E, Marshall J et al. J Allergy Clin Immunol 2024 Apr; 153(4):1155-1161.e4

Mental Health of School-Aged Children Treated with Propranolol or Atenolol for Infantile Hemangioma and Their Parents. Hermans MM, Schappin R, De Laat PCJ, Mendels EJ, Breur JMPJ, Langeveld HR et al. Dermatology 2024; 240(2):216-225

Differential dynamics of TARC during JAK-inhibitor therapy compared to biological therapies targeting type 2 inflammation. Boesjes CM, Bakker DS, Knol EF, De Graaf M, Van Wijk F, De Bruin-Weller MS et al. Clin Exp Allergy 2024 Apr; 54(4):294-296